Etoricoxib 90 mg Type of group
Sponsors
MERCK & CO.INC.,, MERCK SHARP & DOHME PERU S.R.L.,
Unknown Phase
A RANDOMIZED, DOUBLE-BLIND, MULTICENTRIC STUDY TO EVALUATE THE TOLERABILITY AND EFFECTIVENESS OF ETORICOXIB 90 MG PER DAY, VS. SODIC DICLOFENACO 50 MG THREE TIMES A DAY IN PATIENTS WITH OSTEOARTHRITIS.
Active, not recruitingPER-054-02
Target: 6Updated: 2023-09-04
A RANDOMIZED, DOUBLE-BLIND, MULTICENTRIC STUDY TO EVALUATE THE TOLERABILITY AND EFFECTIVENESS OF 90 MG ETORICOXIB ONCE A DAY COMPARED WITH 75 MG SODIUM DICLOFENACO TWICE A DAY IN PATIENTS WITH RHEUMATOID ARTHRITIS.
Active, not recruitingPER-011-03
Target: 577Updated: 2023-09-04
RANDOMIZED, DOUBLE-BLIND STUDY, CONTROLLED BY ACTIVE COMPARATOR IN PARALLEL GROUPS TO EVALUATE THE SAFETY OF ETORICOXIB IN PATIENTS WITH OSTEOARTHRITIS OR RHEUMATOID ARTHRITIS.
Active, not recruitingPER-067-02
Target: 660Updated: 2023-09-04